Nina Dashti-Gibson, Amy L. Olex, Rachel K. Myrick, Alexa M. Barber, David C. Boyd, Emily K. Zboril, Katarzyna M. Tyc, Mikhail G. Dozmorov, Guang-Yu Yang, Nicholas T. Woods, Jose G. Trevino, J Chuck Harrell
Read the abstract →
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
daraxonrasib
Clinical trial64 people · 66 posts · 6 abstracts
Heat trend for this story
Heat now 1·Peak in the comparable set 1 (Oct 23 10:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.
The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.
| Drug / trial | Readout | Setting |
|---|---|---|
| daraxonrasibdaraxonrasib | mOS 13.2 vs 6.7 mo, HR 0.40 | RASolute 302 · 2L mPDAC · Phase 3 |
| daraxonrasib ± GnPdaraxonrasib#PANCREATICCANCER#PDAC | mono ORR 47%; +GnP ORR 55%, DCR 90% | 1L mPDAC · Phase 1 |
The floor rewrote the question from “how long can G12C monotherapy last” to “who first makes first-line pancreatic cancer a standard.” daraxonrasib’s Phase 3 is still the only RAS-inhibitor overall-survival win.
- zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
- VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
- elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
- RM-055Active in daraxonrasib-resistant and RAS-amplification models
Kayla Tyskiewicz, Markus Hippich, Tristan Cates, Gervaise Henry, Gilad Silberberg, Nicole Spanburg, Madeline Westcott, Daniel Ciznadija, Michael Boice, Paul Heverly, Frank Smith, Marianna Zipeto, Stefano Cairo, Sebastian Brabetz
Read the abstract →Nataliya Tovbis Shifrin, Mariela Moreno Ayala, Cristina Blaj, Kevin Chen, Felix Mbuga, Joaquin Pechuan Jorge, Rashi Raghulan, Rich Liang, Linh Tran, Enrico Payson, Alice Kumamoto, Alexander McNamara, Marie Josette Catherine Menard, Michael Weiss, Lillian Seu, Elsa Quintana
Read the abstract →Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer, Melissa Johnson
Read the abstract →Eileen M. O'Reilly, Brian Wolpin, Shubham Pant, Joel Randolph Hecht, Jennifer Valerin, Dae Won Kim, Nilofer Azad, Kyaw Aung, Lin Tao, Sumit Kar, Hina Patel, Rashmi Vora, Aparna Hegde, Alexander Spira, Alexander Starodub, Benjamin Herzberg, Ignacio Garrido-Laguna
Read the abstract →Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal
Read the abstract →M. Elisabeth@ChildrenNeedUs_Score6060 Check out this Daraxonrasib data.
M. Elisabeth@ChildrenNeedUs_Score6060
The Innovation | Medicine@Innov_MedicineScore6060 Anirban Maitra@Aiims1742Score6060
Yakup Ergün@dr_yakupergunScore6060